Literature DB >> 28729476

Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.

Lorenzo Guglielmetti1,2,3, Francis Varaine4, Helena Huerga5, Maryline Bonnet5,6, Michael L Rich7, Carole D Mitnick8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28729476     DOI： 10.1183/13993003.00598-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  3 in total

1.  Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.

Authors:  Hyun Lee; Soohyun Ahn; Na Young Hwang; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Chang-Ki Kim; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan.

Authors:  Philipp du Cros; Atadjan Khamraev; Zinaida Tigay; Tleubergen Abdrasuliev; Jane Greig; Graham Cooke; Krzysztof Herboczek; Tanya Pylypenko; Catherine Berry; Amrita Ronnachit; David Lister; Sebastian Dietrich; Cono Ariti; Khasan Safaev; Bern-Thomas Nyang'wa; Nargiza Parpieva; Mirzagalib Tillashaikhov; Jay Achar
Journal:  ERJ Open Res       Date:  2021-02-08

3.  Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study.

Authors:  Helen Cox; Galo A Goig; Zubeida Salaam-Dreyer; Anzaan Dippenaar; Anja Reuter; Erika Mohr-Holland; Johnny Daniels; Patrick G T Cudahy; Mark P Nicol; Sonia Borrell; Miriam Reinhard; Anna Doetsch; Christian Beisel; Sebastien Gagneux; Robin M Warren; Jennifer Furin
Journal:  J Clin Microbiol       Date:  2022-03-16       Impact factor: 5.948
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.